Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [11C]PF-06809247
PF-06809247 · 1 trial · 1 indication
Binding of \[11C\]PF-06809247 will be assessed by the evaluation of net uptake rate constant Ki (mL/min/g) in the various brain regions modeled, as data permit.
| Arm | Type | Description |
|---|---|---|
| [11C]PF-06809247 | EXPERIMENTAL | A dose intravenous injection of \[11C\]PF-06809247 followed by PET scanning. |
| Name | Type | Description |
|---|---|---|
| [11C]PF-06809247 | DRUG | PET Tracer |
Inclusion Criteria: * Healthy male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria: -Evidence or history of clinically significant hematological...
PF-06809247 is an investigational small molecule developed by Pfizer, Inc. (PFE) as a PET imaging tracer for neuroinflammation. It is also known as [11C]PF-06809247. The compound is in Phase 1 clinical development and has been studied in a single completed trial in the United States.
PF-06809247 is being studied as a positron emission tomography (PET) tracer to image neuroinflammation. It is designed to help visualize inflammatory processes in the brain, which may aid in understanding neurological conditions. The research is at an early stage, with one completed Phase 1 trial in healthy male volunteers.
PF-06809247 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical research program for this imaging agent.
PF-06809247 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The only reported trial, NCT03100136, has been completed.
PF-06809247 has been evaluated in one completed Phase 1 trial, NCT03100136, titled Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tracer. The study enrolled 7 healthy male volunteers in the United States and assessed the tracer's reliability for imaging neuroinflammation.
Yes, PF-06809247 is also known as [11C]PF-06809247. The bracketed carbon-11 label indicates the compound is radiolabeled for use as a PET imaging tracer. Both names refer to the same investigational agent developed by Pfizer.